The role of mucoactive agents in the mechanically ventilated patient: a review of the literature

References

• Oberbeck D, Janssen W, Petersen C. Death in bronchial asthma. Findings and forensic importance. Versicherungsmedizin. 1993 Apr 1;45(2):58–63.
   PubMedGoogle Scholar
• Bilton D, Stanford G. The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care? Curr Opin Pulm Med. 2014 Nov;20(6):601–606.
   PubMed Web of Science ®Google Scholar
• Houtmeyers E, Gosselink R, Gayan-Ramirez G, et al. The effect of drugs on mucus clearance. Eur Respir J. 1999;14:452–467.
   PubMed Web of Science ®Google Scholar
• Shelly MP. Effects of dry inspired gases in anaesthesia. Br J Hosp Med. 1988;40:81.
   PubMed Web of Science ®Google Scholar
• Strickland SL. Year in review 2014: air clearance. Respir Care. 2015 April 1; 60(4):603–605.
   PubMed Web of Science ®Google Scholar
• Branson RD. Secretion management in the mechanically ventilated patient. Respir Care. 2007 October 1; 52(10):1328–1347.
   PubMed Web of Science ®Google Scholar
• Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care. 2002 Jul;47(7):818–822.
   PubMedGoogle Scholar
• Rubin BK. Physiology of airway mucus clearance. Respir Care. 2002;47(7):761–768.
   PubMedGoogle Scholar
• Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest. 2009;135(2):505–512.
   PubMed Web of Science ®Google Scholar
• Rubin BK, Priftis KN, Schmidt HJ, et al. Secretory hyperresponsiveness and pulmonary mucus hypersecretion. Chest. 2014;146(2):496–507.
   PubMed Web of Science ®Google Scholar
• Burgel P-R, Nadel JA. Plugging (publicising) to prevent mucous plugging. Eur Respir J. 2010 Dec;36(6):1236–1238. DOI:10.1183/09031936.00100610
   PubMed Web of Science ®Google Scholar
• Panchabhai TS, Mukhopadhyay S, Sehgal S, et al. Plugs of the air passages: a clinicopathologic review. Chest. 2016;150(5):1141–1157.
   PubMed Web of Science ®Google Scholar
• van der Hoeven SM, Binnekade JM, de Borgie CA, et al. Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial. Trials. 2015 Sep 2;16:389.
   PubMed Web of Science ®Google Scholar
• Konrad F, Schoenberg MH, Wiedmann H, et al. The application of n-acetylcysteine as an antioxidant and mucolytic in mechanical ventilation in intensive care patients. A prospective, randomized, placebo-controlled, double-blind study. Anaesthesist. 1995 Sep;44(9):651–658.
   PubMed Web of Science ®Google Scholar
• Masoompour SM, Anushiravani A, Tafaroj Norouz A. Evaluation of the effect of nebulized N-acetylcysteine on respiratory secretions in mechanically ventilated patients: randomized clinical trial. Iran J Med Sci. 2015;40(4):309–315.
   PubMed Web of Science ®Google Scholar
• Shien SL. Prophylactic use of nebulized hypertonic saline in mechanically ventilated children: a randomized blinded pilot study. Respir Care. 2016 May 5;61:586–592. DOI:10.4187/respcare.04418
   PubMed Web of Science ®Google Scholar
• Youness HA, Mathews K, Elya MK, et al. Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients. J Aerosol Med Pulm Drug Delivery. 2012;25(6):342–348.
   PubMed Web of Science ®Google Scholar
• Prodhan P, Greenberg B, Bhutta A, et al. Recombinant human deoxyribonuclease improves atelectasis in mechanically ventilated children with cardiac disease. Congenit Heart Dis. 2009;4(3):166–173.
   PubMed Web of Science ®Google Scholar
• Zitter JN, Maldjian P, Brimacombe M, et al. Inhaled Dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients. J Crit Care. 2013 Apr;28(2):218.e1-7.
   PubMed Web of Science ®Google Scholar
• Frass M, Dielacher C, Linkesch M, et al. Influence of potassium dichromate on tracheal secretions in critically ill patients. Chest. 2005 Mar;127(3):936–941.
   PubMed Web of Science ®Google Scholar
• Baranwal AK, Murthy AS, Singhi SC. High-dose oral ambroxol for early treatment of pulmonary acute respiratory distress syndrome: an exploratory, randomized, controlled pilot trial. J Trop Pediatr. 2015 Oct;61(5):339–350. Epub 2015 Jun 30. DOI:10.1093/tropej/fmv033
   PubMed Web of Science ®Google Scholar
• Reinero CR, Lee-Fowler TM, Dodam JR, et al. Endotracheal nebulization of N-acetylcysteine increases airway resistance in cats with experimental asthma. J Feline Med Surg. 2011 Feb;13(2):69–73. Epub 2010 Dec 9. DOI:10.1016/j.jfms.2010.09.010
   PubMed Web of Science ®Google Scholar
• Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552–1560.
   PubMed Web of Science ®Google Scholar
• Mata AF, Sarnaik AA. Bronchoscopy with N-acetylcysteine lavage in severe respiratory failure from pertussis infection. Pediatrics. 2013 Nov;132(5):e1418–23. Epub 2013 Oct 28.
   PubMed Web of Science ®Google Scholar
• Liu S, Yu SY. Protective effect of N-acetylcysteine on acute lung injury caused by exposure to rocket liquid propellant. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 Oct;16(10):611–614.
   PubMedGoogle Scholar
• Najafi A, Mojtahedzadeh M, Ahmadi KH, et al. The immunological benefit of higher dose N-acetyl cysteine following mechanical ventilation in critically ill patients. Daru. 2014 Jul 15;22:57.
   PubMed Web of Science ®Google Scholar
• Sarrell EM, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest. 2002;122:2015–2020.
   PubMed Web of Science ®Google Scholar
• Mandelberg A, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest. 2003;123:481–487.
   PubMed Web of Science ®Google Scholar
• Tal G, Cesar K, Oron A, et al. Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience. Isr Med Assoc J. 2006;8:169–173.
   PubMed Web of Science ®Google Scholar
• Kuzik BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr. 2007;151:266–70.270.e1.
   PubMed Web of Science ®Google Scholar
• Luo Z, Liu E, Luo J, et al. Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis. Pediatr Int. 2010;52:199–202.
   PubMed Web of Science ®Google Scholar
• Florin TA, Shaw KN, Kittick M. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr. 2014;168(7):664–670.
   PubMed Web of Science ®Google Scholar
• Jacobs JD, Foster M, Wan J, et al. 7% Hypertonic saline in acute bronchiolitis: a randomized controlled trial. Pediatrics. 2014;133(1):e8–e13.
   PubMed Web of Science ®Google Scholar
• Wu S, Baker C, Lang ME, et al. Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial. JAMA Pediatr. 2014;168(7):657–663.
   PubMed Web of Science ®Google Scholar
• Gupta HV, Gupta VV, Kaur G, et al. Effectiveness of 3% hypertonic saline nebulization in acute bronchiolitis among Indian children: a quasi-experimental study. Perspect Clin Res. 2016 Apr-Jun;7(2):88–93.
   PubMedGoogle Scholar
• Zhang L, Mendoza-Sassi RA, Klassen TP, et al. Nebulized hypertonic saline for acute bronchiolitis: a systematic review. Pediatrics. 2015 Oct;36(4):1687–1701. DOI:10.1542/peds.2015-1914
   Web of Science ®Google Scholar
• Baron J, El-Chaar G. Hypertonic saline for the treatment of bronchiolitis in infants and young children: a critical review of the literature. J Pediatr Pharmacol Therapeutics: JPPT. 2016 Jan-Feb;21(1):7–26.
   PubMedGoogle Scholar
• Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502.
   PubMed Web of Science ®Google Scholar
• Reeves EP, McCarthy C, McElvaney OJ, et al. Inhaled hypertonic saline for cystic fibrosis: reviewing the potential evidence for modulation of neutrophil signalling and function. World J Crit Care Med. 2015 Aug 4;4(3):179–191. DOI:10.5492/wjccm.v4.i3.179.eCollection2015
   PubMedGoogle Scholar
• Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006 Jan 19;354(3):241–250.
   PubMed Web of Science ®Google Scholar
• Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2009 Apr 15;(2): CD001506. 10.1002/14651858.CD001506.pub3
   PubMed Web of Science ®Google Scholar
• Bennett WD, Wu J, Fuller F, et al. Duration of action of hypertonic saline on mucociliary clearance in the normal lung. J Appl Physiol. 2015 Jun 15;118(12):1483–1490. Epub 2015 Apr 24. DOI:10.1152/japplphysiol.00404.2014
   PubMed Web of Science ®Google Scholar
• Bencova A, Vidan J, Rozborilova E, et al. The impact of hypertonic saline inhalation on mucociliary clearance and nasal nitric oxide. J Physiol Pharmacol. 2012 Jun;63(3):309–313.
   PubMed Web of Science ®Google Scholar
• Brivio A, Conese M, Gambazza S, et al. Pilot randomized controlled trial evaluating the effect of hypertonic saline with and without hyaluronic acid in reducing inflammation in cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2016 May 5. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. Jama. 1968;205(5):312–313.
   PubMed Web of Science ®Google Scholar
• Yang C, Chilvers M, Montgomery M, et al. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2016;4:CD001127. DOI:10.1002/14651858.CD001127.pub3
   PubMed Web of Science ®Google Scholar
• Claudius C, Perner A, Møller MH. Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Syst Rev. 2015 Nov 8;4:153.
   PubMedGoogle Scholar
• Rubin BK. Aerosol medications for treatment of mucus clearance disorders. Respir Care. 2015 Jun;60(6):825–829. discussion 830-32.
   PubMed Web of Science ®Google Scholar
• Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372:415–417.
   PubMed Web of Science ®Google Scholar
• Chen JH, Stoltz DA, Karp PH, et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell. 2010;143:911–923.
   PubMed Web of Science ®Google Scholar
• Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009;119:2613–2622.
   PubMed Web of Science ®Google Scholar
• Gustafsson JK, Ermund A, Ambort D, et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med. 2012;209:1263–1272.
   PubMed Web of Science ®Google Scholar
• Chen EYT, Yang N, Quinton PM, et al. A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):L542–L549.
   PubMed Web of Science ®Google Scholar
• Cooper JL, Quinton PM, Ballard ST. Mucociliary transport in porcine trachea: differential effects of inhibiting chloride and bicarbonate secretion. Am J Physiol Lung Cell Mol Physiol. 2013;304(3):L184–L190.
   PubMed Web of Science ®Google Scholar
• Stigliani M, Manniello MD, Zegarra-Moran O, et al. Rheological properties of cystic fibrosis bronchial secretion and in vitro drug permeation study: the effect of sodium bicarbonate. J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):337–345. Epub 2016 Jan 7.
   PubMed Web of Science ®Google Scholar
• Nolan SJ, Thornton J, Murray CS, et al. Inhaled mannitol for cystic fibrosis. Cochrane Database Syst Rev. 2015 Oct 9;(10): CD008649. 10.1002/14651858.CD008649.pub2
   PubMed Web of Science ®Google Scholar
• Daviskas E, Rubin BK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med. 2013 Feb;7(1):65–75. DOI:10.1586/ers.12.72
   PubMed Web of Science ®Google Scholar
• Hoffer-Schaefer A, Rozycki HJ, Yopp MA, et al. Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections. Respir Care. 2014 May;59(5):631–636. Epub 2013 Sep 3. DOI:10.4187/respcare.02640
   PubMed Web of Science ®Google Scholar
• Bennett WD, Kala A, Duckworth H, et al. Effect of a single 1200 Mg dose of Mucinex® on mucociliary and cough clearance during an acute respiratory tract infection. Respir Med. 2015 Nov;109(11):1476–1483. Epub 2015 Oct 9. DOI:10.1016/j.rmed.2015.09.017
   PubMed Web of Science ®Google Scholar
• Adler M. Efficacy and safety of a fixed-combination homeopathic therapy for sinusitis. Adv Ther. 1999 Mar-Apr;16(2):103–111.
   PubMed Web of Science ®Google Scholar
• Cataldi M, Sblendorio V, Leo A, et al. Biofilm-dependent airway infections: a role for ambroxol? Pulm Pharmacol Ther. 2014 Aug;28(2):98–108. Epub 2013 Nov 16. DOI:10.1016/j.pupt.2013.11.002
   PubMed Web of Science ®Google Scholar
• Mall MA. Unplugging Mucus in cystic fibrosis and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016 Apr;13(Suppl 2):S177–85.
   PubMed Web of Science ®Google Scholar
• Graeber SY, Zhou-Suckow Z, Schatterny J, et al. Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease. Am J Respir Cell Mol Biol. 2013 Sep;49(3):410–417.
   PubMed Web of Science ®Google Scholar
• Jelic S, Cunningham JA, Factor P. Clinical review: airway hygiene in the intensive care unit. Crit Care. 2008;12(2):209.
   PubMed Web of Science ®Google Scholar